Open AccessReal-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study
Author(s) -
Olga Tronina,
Magdalena Durlik,
Iwona Orłowska,
Beata Lorenc,
Tadeusz Wojciech Łapiński,
Aleksander Garlicki,
Dorota Dybowska,
Dorota ZarębskaMichaluk,
Magdalena TudrujekZdunek,
Jolanta Citko,
Ewa Janczewska,
Marcin Kaczmarczyk,
Jerzy Jaroszewicz,
Rafał Krygier,
Jakub Klapaczyński,
Beata Dobracka,
Jolanta Białkowska-Warzecha,
Anna Piekarska,
Krzysztof Simon,
Waldemar Halota,
Małgorzata Pawłowska,
Krzysztof Tomasiewicz,
Robert Flisiak
Publication year - 2021
Publication title -
annals of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.886
H-Index - 33
eISSN - 1792-7463
pISSN - 1108-7471
DOI - 10.20524/aog.2021.0595
Subject(s) - medicine , paritaprevir , ombitasvir , sofosbuvir , regimen , renal function , hemodialysis , transplantation , kidney transplantation , ledipasvir , gastroenterology , hepatitis c virus , ribavirin , immunology , virus
Patients who undergo hemodialysis (HD) or kidney transplantation (KTx) previously had limited possibilities for treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals (DAA) give these patients a chance of virus eradication and safe transplantation. The aim of this study was to evaluate the effectiveness and safety of DAA in KTx and HD patients in real-world settings.